Performance of a sustainable asphalt mix incorporating high RAP content and novel bio-derived binder

The recent drive to find ways to increase sustainability and decrease costs in asphalt paving has led researchers to find innovative ways to incorporate more recycled materials and bio-derived binders into mixes with varying success. A new novel bio-derived binder made from refined pine chemistry stabilised with a polymer can increase the sustainability of asphalt mixes while maintaining pavement performance. Laboratory performance testing was conducted on asphalt mixes containing 50% Reclaimed Asphalt Pavement (RAP) by mix weight and the novel bio-derived binder. Results show that the bio-derived binder outperforms the conventional 50/70 pen grade binder mixes with respect to resistance to thermal cracking and adequately passes all requirements for pavements with 20-year design loadings of less than 30 million ESALs. This research shows that asphalt mixes containing 50% RAP and a bio-derived binder can be designed to pass performance criteria at low, intermediate, and high temperatures without the need of neat bitumen

Effect of two novel bio-based rejuvenators on the performance of 50% RAP mixes–a statistical study on the complex modulus of asphalt binders and asphalt mixtures

An experimental study was conducted to evaluate the effectiveness of two bio-additives as rejuvenators on the properties of asphalt mixtures containing 50% RAP and their binder constituents containing 37% RAP binder. Before mixing, the rejuvenators were blended with fresh bitumen and the extracted and recovered RAP bitumen, and changes in the rheological properties of the binders were assessed using performance grading (PG) criteria. The results showed that both rejuvenators could improve the low-temperature performance of the aged RAP binder and restore its low-temperature properties. Master curves for the unaged, RTFO-aged, and PAV aged blends were constructed using both the Christensen-Anderson-Marasteanu (CAM) model and the Sigmoidal models. A comparative statistical analysis conducted on the models indicated no significant difference between the measured and predicted complex modulus values at any aging conditions. The pairwise statistical comparison between the two models showed that at unaged conditions, they can perfectly overlap as the p-values were greater than the level of significance. However, for the PAV-aged binders, this behaviour appears to weaken due to the brittle behaviour of the binders. Further statistical analyses revealed no significant differences between the two models at unaged conditions, however, as the binders where subjected to aging, significant differences between the two models began to appear. Mixing was performed in two locations: lab and plant, while compaction was performed only in the lab. After mixing and compaction, mixtures were evaluated for their stiffness characteristics through dynamic modulus testing. Compared to the control mixture, rejuvenated mixtures showed lower dynamic modulus values specially at high temperatures. A statistical comparison between the lab-produced, lab-compacted mixtures and plant-produced, lab compacted mixtures showed that both the rejuvenation and the location of mixing were significant factors in the stiffness measurements

Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis

International audienceMultiple sclerosis, the most common cause of neurological disability in young population after trauma, represents a significant public health burden. Current challenges associated with management of multiple sclerosis (MS) patients stem from the lack of biomarkers that might enable stratification of the different clinical forms of MS and thus prompt treatment for those patients with progressive MS, for whom there is currently no therapy available. In the present work we analyzed a set of thirty different plasma cytokines, chemokines and growth factors present in circulation of 129 MS patients with different clinical forms (relapsing remitting, secondary progressive and primary progressive MS) and 53 healthy controls, across two independent cohorts. The set of plasma analytes was quantified with Luminex xMAP technology and their predictive power regarding clinical outcome was evaluated both individually using ROC curves and in combination using logistic regression analysis. Our results from two independent cohorts of MS patients demonstrate that the divergent clinical and histology-based MS forms are associated with distinct profiles of circulating plasma protein biomarkers, with distinct signatures being composed of chemokines and growth/angiogenic factors. With this work, we propose that an evaluation of a set of 4 circulating biomarkers (HGF, Eotaxin/CCL11, EGF and MIP-1β/CCL4) in MS patients might serve as an effective tool in the diagnosis and more personalized therapeutic targeting of MS patients